1. Volume 70, Issue 1, Pages 35-41 (July 2016)
A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer 
Kazuhiro Yoshimura, Takafumi Minami, Masahiro Nozawa, Takahiro Kimura, Shin Egawa, Hiroyuki Fujimoto, Akira Yamada, Kyogo Itoh, Hirotsugu Uemura 
European Urology 
Volume 70, Issue 1, Pages (July 2016)
DOI: /j.eururo
Copyright © 2016 European Association of Urology Terms and Conditions

2. Fig. 1 Disposition of patients: study flowchart.
European Urology  , 35-41DOI: ( /j.eururo )
Copyright © 2016 European Association of Urology Terms and Conditions

3. Fig. 2
Waterfall plots of prostate-specific antigen decline at 12 wk after administration.
Dex=dexamethasone.
European Urology  , 35-41DOI: ( /j.eururo )
Copyright © 2016 European Association of Urology Terms and Conditions

4. Fig. 3
(a) Prostate-specific antigen (PSA) progression-free survival is shown. The vaccination arm is shown as a red line; the dexamethasone (Dex) arm is shown as a blue line. Median PSA progression-free survival was 665 d in the vaccination arm and 210 d in the Dex arm. (b) Time to initiation of chemotherapy is shown. The vaccination arm is shown as a red line; the Dex arm is shown as a blue line. Median time to initiation of chemotherapy was 1576 d in the vaccination arm and 719 d in the Dex arm. (c) Overall survival is shown. The vaccination arm is shown as a red line; the Dex arm is shown as a blue line. Median overall survival was 2219 d in the vaccination arm and 1054 d in the Dex arm.
CI=confidence interval; Dex=dexamethasone.
European Urology  , 35-41DOI: ( /j.eururo )
Copyright © 2016 European Association of Urology Terms and Conditions